Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 28, 2026, 7:29 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 411 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Food Effect in Healthy Participants Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Characterization Of The Effect Of Food On Palbociclib (PD-0332991) Absorption

NCT01904747
View directory record Official record
Conditions
Healthy
Interventions
Palbociclib administered Fasted, Palbociclib administered Fed high calorie, Palbociclib administered Fed low calorie, Palbociclib administered Fed moderate calorie
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Dec 16, 2013 · Synced Sep 28, 2026, 7:29 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study To Determine The Effect Of Food And Strong CYP3A4 Enzyme Inhibitor On PF-04449913 Drug Levels

NCT01749085
View directory record Official record
Conditions
Healthy Volunteers
Interventions
PF-04449913, ketoconazole
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 9, 2013 · Synced Sep 28, 2026, 7:29 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Single Ascending Dose Study to Evaluate Pharmacokinetics and Food-Effect in Healthy Volunteers

NCT02853643
View directory record Official record
Conditions
Healthy Volunteers
Interventions
ASN002
Drug
Lead sponsor
Asana BioSciences
Industry
Eligibility
18 Years to 60 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Apr 13, 2023 · Synced Sep 28, 2026, 7:29 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study in Normal Healthy People, Testing Different Versions of a Pill That Will be Used to Treat Rheumatoid Arthritis.

NCT00838058
View directory record Official record
Conditions
Rheumatoid Arthritis, Healthy Volunteers
Interventions
CE 224,535
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 13, 2009 · Synced Sep 28, 2026, 7:29 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects of Pecan Nut Snacks v Equicaloric Snacks on Appetite, Food Intake, Metabolism, Hormones and Biomarkers

NCT04484974
View directory record Official record
Conditions
Overweight and Obesity
Interventions
Pecan snack, Tortilla chip snack
Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
20 Years to 50 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jul 4, 2024 · Synced Sep 28, 2026, 7:29 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of Abemaciclib in Healthy Participants

NCT02672423
View directory record Official record
Conditions
Healthy
Interventions
Abemaciclib Capsules (Reference Formulation), Abemaciclib Tablet (Test Formulation)
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
127 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
2
States / cities
Daytona Beach, Florida • Evansville, Indiana
Source: ClinicalTrials.gov public record
Updated Jan 3, 2019 · Synced Sep 28, 2026, 7:29 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effect of Food on the Oral Bioavailability of Relacorilant in Healthy Subjects

NCT06094738
View directory record Official record
Conditions
Healthy
Interventions
Relacorilant under fasted conditions, Relacorilant after a high-fat meal, Relacorilant after a low-fat meal
Drug
Lead sponsor
Corcept Therapeutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Oct 22, 2023 · Synced Sep 28, 2026, 7:29 AM EDT
Completed Phase 1Phase 2 Interventional

Adaptive Phase I HCV Study With Nucleoside Analogue, in Combination With Interferon and Ribavirin

NCT00382798
View directory record Official record
Conditions
Healthy Volunteers, Hepatitis C Virus
Interventions
RO5024048
Drug
Lead sponsor
Pharmasset
Industry
Eligibility
18 Years to 65 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
7
States / cities
San Francisco, California • Aurora, Colorado • Gainesville, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2009 · Synced Sep 28, 2026, 7:29 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Food Effect and Bioequivalence Study of Simufilam Tablets in Healthy Volunteers

NCT04932655
View directory record Official record
Conditions
Healthy Volunteers
Interventions
simufilam
Drug
Lead sponsor
Cassava Sciences, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Aug 21, 2023 · Synced Sep 28, 2026, 7:29 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

A Study of LY3509754 in Healthy Non-Japanese and Japanese Participants

NCT04586920
View directory record Official record
Conditions
Healthy
Interventions
LY3509754, Placebo, Itraconazole, Midazolam
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
104 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
2
States / cities
Anaheim, California • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 2, 2025 · Synced Sep 28, 2026, 7:29 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Understand the Effect of Low-Fat and High-Fat Meals on the Medicine Called PF-07284890 in Healthy Adults

NCT05349864
View directory record Official record
Conditions
Healthy Participants
Interventions
PF-07284890 Treatment A, PF-07284890 Treatment B, PF-07284890 Treatment C
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 14, 2024 · Synced Sep 28, 2026, 7:29 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics of Fixed-Dose Combination Tablet of Bemnifosbuvir and Ruzasvir

NCT06204679
View directory record Official record
Conditions
Healthy Volunteer Study
Interventions
Bemnifosbuvir (BEM)/Ruzasvir (RZR) FDC under fasting conditions, Bemnifosbuvir (BEM)/Ruzasvir (RZR) FDC under fed conditions, Bemnifosbuvir (BEM) and Ruzasvir (RZR) as reference formulation under fasting conditions
Drug
Lead sponsor
Atea Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Sep 28, 2026, 7:29 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Compare How the Body Absorbs, Distributes and Excretes the Drug Selitrectinib (BAY2731954) Given as Two Different Tablet Formulations or as Liquid Formulations Including the Effect of Food on the Absorption, Distribution or Excretion of the Different Formulations in Healthy Participants

NCT04771390
View directory record Official record
Conditions
Solid Tumors Harboring NTRK Fusion
Interventions
Selitrectinib (BAY2731954) Adult tablet, Selitrectinib (BAY2731954) Pediatric tablet, Selitrectinib (BAY2731954) Oral solution, Selitrectinib (BAY2731954) Oral suspension
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 55 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
2
States / cities
Glendale, California • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 24, 2021 · Synced Sep 28, 2026, 7:29 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Trial to Characterize Differences in Blood Levels of Different Lots of Centanafadine QD XR and to Understand the Effect of Food on Blood Levels

NCT07253441
View directory record Official record
Conditions
Attention Deficit Disorder With Hyperactivity
Interventions
CTN XR (TBM), CTN SR, CTN XR (Clin)
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
174 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
2
States / cities
Lenexa, Kansas • Millcreek, Utah
Source: ClinicalTrials.gov public record
Updated Dec 10, 2025 · Synced Sep 28, 2026, 7:29 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate Safety, Tolerability, and the PK Profile of TBI-223 in Healthy Subjects

NCT04865536
View directory record Official record
Conditions
Tuberculosis, Tuberculosis, Pulmonary
Interventions
TBI-223 1800 mg, TBI-223 2400mg, TBI-223 Placebo
Drug
Lead sponsor
Global Alliance for TB Drug Development
Other
Eligibility
19 Years to 50 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Fair Lawn, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 4, 2025 · Synced Sep 28, 2026, 7:29 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Drug-Food Interaction Study Between Colchicine and Grapefruit Juice

NCT00984009
View directory record Official record
Conditions
Pharmacokinetics
Interventions
Colchicine, Grapefruit Juice
Drug · Other
Lead sponsor
Mutual Pharmaceutical Company, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Nov 20, 2011 · Synced Sep 28, 2026, 7:29 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of Two Dosage Forms of LY2886721 in Healthy Participants

NCT01775904
View directory record Official record
Conditions
Healthy Volunteers
Interventions
LY2886721 in a Capsule, LY2886721 in an orally disintegrating tablet (ODT)
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 18, 2019 · Synced Sep 28, 2026, 7:29 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Bioequivalence Between Immediate Release Tablets and Minitablets of Deucravacitinib (BMS-986165), and the Effect of Food and pH on the Drug Levels of the Minitablets in Healthy Adults

NCT06851871
View directory record Official record
Conditions
Healthy Participants
Interventions
Deucravacitinib, Famotidine
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 55 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Apr 28, 2025 · Synced Sep 28, 2026, 7:29 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability and Pharmacokinetics of Single Doses of TS-134 in Healthy Volunteers

NCT03746067
View directory record Official record
Conditions
Healthy Volunteers
Interventions
TS-134, Placebo
Drug
Lead sponsor
Taisho Pharmaceutical R&D Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Nov 18, 2018 · Synced Sep 28, 2026, 7:29 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Food Effect and Relative Bioavailability Study of Rilzabrutinib in Healthy Participants

NCT06342700
View directory record Official record
Conditions
Autoimmune Disorder, Healthy Volunteers
Interventions
Rilzabrutinib crystalline form, Rilzabrutinib amorphous form
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 55 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 2, 2025 · Synced Sep 28, 2026, 7:29 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Assess the Safety, Tolerability, PK, ECG Effects, Food Effect, and Drug-drug Interaction (DDI) of Hormonal Contraceptives of PTI-428 in Healthy Female Volunteers

NCT02846142
View directory record Official record
Conditions
Healthy Volunteer
Interventions
PTI-428, Placebo, ethinyl estradiol and levonorgestrel
Drug · Other
Lead sponsor
Proteostasis Therapeutics, Inc.
Industry
Eligibility
18 Years to 55 Years · Female only
Enrollment
94 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated May 23, 2018 · Synced Sep 28, 2026, 7:29 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of ASC50 Tables in Healthy Participants and Participants With Plaque Psoriasis

NCT07024602
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
ASC50 tablets or matching placebo
Drug
Lead sponsor
Ascletis Pharma (China) Co., Limited
Industry
Eligibility
18 Years to 65 Years
Enrollment
94 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 16, 2025 · Synced Sep 28, 2026, 7:29 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effect of Food and Proton Pump Inhibitor on the Pharmacokinetics of ZN-A-1041 in Healthy Participants

NCT07329972
View directory record Official record
Conditions
Healthy Volunteers
Interventions
ZN-A-1041 Formulation 1, ZN-A-1041 Formulation 2, Rabeprazole
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
2
States / cities
Daytona Beach, Florida • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated May 10, 2026 · Synced Sep 28, 2026, 7:29 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Safety, Tolerability, and Interactions of ABBV-CLS-616 Oral Tablets in Healthy Adult Participants

NCT06698926
View directory record Official record
Conditions
Healthy Volunteer
Interventions
ABBV-CLS-616, Placebo, Itraconazole
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 65 Years
Enrollment
110 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Grayslake, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 14, 2026 · Synced Sep 28, 2026, 7:29 AM EDT